1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Sinocelltech Group Limited Class A

Sinocelltech Group Limited Class A

SSSE:688520
32.79
CNY
-0.90
(-2.67%)
-1.77EPS
16.09BMarket Cap
Oct 31Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.22
0.01
0.01
0.01
- -
0.31
2.35
4.24
5.39
3.65
3.04
Basic EPS, GAAP
-0.03
-0.31
-1
-2.09
-1.74
-1.99
-1.19
-0.89
0.24
-1.32
-1.74
Free Cash Flow per Basic Share
-0.39
-0.36
-0.42
-1.61
-1.6
-2.43
-2.25
-2
-0.54
-1.15
- -
Dividend per Share
0.01
0.01
0.01
0.03
0.06
0.07
0.19
0.26
0.23
0.26
0.23
Book Value per Share
0.22
0.46
-0.06
0.09
1.36
-0.52
-0.53
-1.35
0.32
0.29
1.35
Tangible Book Value per Share
0.17
0.41
-0.14
0.02
1.29
-0.6
-0.81
-1.77
-0.14
-0.17
0.94
Basic Weighted Avg Shares
453
453
453
380
409
436
436
445
466
428
447
Sales/Revenue/Turnover
98
6
3
3
- -
134
1,023
1,887
2,513
1,560
1,360
Operating Margin (%)
-77.06
-2,385.29
100
-30,079.93
-216,142.44
-622.72
-26.66
8.24
27.02
-21.63
-38.86
Depreciation Expense
18
26
4
37
40
52
66
115
157
180
- -
Net Income, GAAP
-12
-141
-453
-795
-713
-867
-519
-396
112
-565
-777
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-12.37
-2,357.52
-15,387.11
-30,122.06
-217,117.74
-645.01
-50.72
-20.98
4.46
-36.2
-57.16
Working Capital
8
47
-146
28
569
-77
159
-966
-552
-837
-291
LT Debt
121
116
101
302
403
705
739
1,093
945
846
861
Total Equity
80
168
-24
35
588
-231
-242
-606
135
120
640
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
23.52
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
8.93
- -
- -
Return on Common Equity (%)
- -
-109.17
- -
- -
-227.23
- -
- -
- -
- -
-419.7
-185.62

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,287
2,217
1,915
LT Borrowings
797
878
832
LT Finance Leases
49
43
29
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
445
470
470
Market Capitalization
19,287
18,964
16,090

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,898
2,607
2,054
Cash, Cash Equivalents & STI
859
1,562
1,027
Accounts Receivable, Net
541
390
477
Inventories
336
346
356
Total Current Liabilities
2,735
2,659
2,345
Payables & Accruals
- -
- -
- -
ST Debt
2,287
2,217
1,915
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-23.47%
-10.83%
Free Cash Flow
- -
13.9%
96.45%
Net Income, GAAP
- -
-155%
-604.55%
Sales/Revenue/Turnover
- -
8,318.76%
-37.91%
Total Cash Common Dividend
- -
47.28%
5.42%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
613
692
632
576
2,513
2025
520
452
- -
248
1,560
2026
323
336
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.12
0.05
-0.09
0.24
2025
0.13
-0.22
- -
-0.71
-1.32
2026
-0.41
-0.4
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.06
0.06
0.05
0.23
2025
0.05
0.05
- -
0.07
0.26
2026
0.05
0.06
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Liang Zhi Xie
Full Time Employees
2,200
Sector
Health technology
Industry
Biotechnology
Address
No. 31 Kechuang 7th Street Beijing BE China 100176
IPO Date
Jun 22, 2020
Website
sinocelltech.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Sinocelltech Group Limited (688520.SS) is a China-based biopharmaceutical company principally engaged in the research, development, manufacturing, and commercialization of biologic drugs, including monoclonal antibodies, recombinant proteins, and vaccines targeting oncology, autoimmune diseases, infectious diseases, genetic disorders such as hemophilia, and other therapeutic areas. The company offers marketed products in China such as SCT800 (adalimumab biosimilar for Crohn's disease, rheumatoid arthritis, and psoriasis), SCT400 and SCT200 (recombinant coagulation factor VIII for hemophilia A), SCT630 (ripertamab, a CD20 monoclonal antibody for diffuse large B-cell lymphoma), SCT510 (bevacizumab biosimilar authorized in June 2023), and multiple recombinant novel coronavirus vaccines including a beta/omicron variant trimeric protein vaccine approved in December 2023 and a two-valent alpha/beta variant vaccine approved in December 2022; its pipeline encompasses over nine clinical-stage candidates like SC-101 (monoclonal antibody for autoimmune diseases in Phase II), SC-102 (bispecific antibody for cancer in Phase I), SCT1000, SCT650C, SCTB35, SCTV01 (14-valent HPV vaccine for cervical cancer prevention), and preclinical assets including trispecific antibodies and cell therapies for chronic kidney disease. Founded in 2002 by Dr. Xie Liangzhi and headquartered at No. 31 Kechuang 7th Street, Beijing Economic-Technological Development Area, Beijing, China, Sinocelltech operates primarily in China with products marketed domestically and select international outreach in Europe and America, supported by advanced platforms for protein expression, cell line development, fed-batch culture, and purification; it employs approximately 2,277 people and functions as a subsidiary of Lhasa Alike Investment Consulting Co., Ltd. Recent developments include the February 2025 approval in China of finotonlimab, a PD-1 inhibitor monoclonal antibody for recurrent/metastatic head and neck squamous cell carcinoma; a planned private placement of up to CNY 900 million to controlling shareholder Lhasa Ailike in August 2025 to supplement working capital; and subsidiary clinical trial approvals for anti-tumor injections as of June 2025, amid ongoing commercialization challenges from procurement price reductions and market contraction in recombinant factor VIII in the first half of 2025.